Please fill out the form below and we will gladly respond as soon as possible.
A 2022 study explored how sarcoma patients feel about long-term surveillance imaging after treatment, highlighting the emotional, financial, and practical challenges that can come with ongoing follow-up care. The study, led by Sarah C. Tepper, Anna K. Holten, Cara A. Cipriano, and colleagues evaluated patient concerns surrounding surveillance imaging through the “Sarcoma Surveillance Survey.” The […]
A new multi-center retrospective study from three major U.S. sarcoma centers has analyzed outcomes in patients with localized synovial sarcoma, making it one of the largest modern cohorts to examine how tumor characteristics and treatment modality affect recurrence and survival in this disease. The study, led by Stefano Testa, Maggie Yuxi Zhou, and colleagues from […]
New industry analyses project continued growth in the North America synovial sarcoma treatment market, with a predicted compound annual growth rate (CAGR) of 4.2% from 2026 to 2033. The report reflects increasing momentum in rare cancer research, including advances in targeted therapy, immunotherapy, and precision medicine for synovial sarcoma. What’s Driving Growth in Synovial Sarcoma […]
Synovial sarcoma is a rare and aggressive soft tissue cancer that most often develops near the joints of the arms or legs. In very rare cases, however, it can appear in unusual locations — including the skull and brain region. A newly published case report describes a patient diagnosed with primary cranial synovial sarcoma who […]
We are incredibly honored to share that the Synovial Sarcoma Foundation received First Place in the Advocacy in Action Award at the 16th Annual SPAGN Conference in Stockholm, Sweden. Hosted by the Sarcoma Patient Advocacy Global Network (SPAGN), this award recognizes advocacy initiatives making a meaningful impact for sarcoma patients, families, clinicians, and researchers around […]
[Philadelphia, PA] The Synovial Sarcoma Foundation (SSF) is honored to welcome Lucia Manzinello Belluco and Roberto Belluco to its Board of Directors as the organization’s first European board members. Their appointment marks an important step in expanding the foundation’s international reach and strengthening collaboration across the global synovial sarcoma community. Lucia brings more than 20 […]
Developing treatments for rare cancers like synovial sarcoma remains one of the biggest challenges in modern medicine—but recent progress shows what’s possible. One major milestone came with the FDA approval of Tecelra, the first engineered T-cell therapy approved for a solid tumor in the U.S., including synovial sarcoma. Why Rare Cancers Face Unique Challenges Synovial […]
Synovial sarcoma is a rare and aggressive soft tissue cancer, but new research is helping us better understand how it behaves—and how it may be treated in the future. A recent study using advanced single-cell RNA sequencing has identified four distinct subtypes of synovial sarcoma, each with unique biological features and potential treatment pathways. Why […]
A new Phase 1/2 trial in Ewing sarcoma, just profiled in Clinical Trial Vanguard and published in Nature Medicine, delivered the kind of result the synovial sarcoma community should be watching closely. The trial paired trabectedin with low-dose irinotecan to target the EWS::FLI1 fusion, the oncogenic driver of Ewing sarcoma. For more than a decade, […]
A recent case report highlights a rare GLI1-altered mesenchymal tumor presenting in the pleura (lining of the lung), a location where tumors can closely resemble synovial sarcoma. This case underscores a critical challenge in rare cancers — different tumors can appear similar under imaging and even under the microscope, making accurate diagnosis essential for appropriate […]